
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (MAZE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MAZE · as of Jun 8, 2026
Key Statistics
Explore Maze Therapeutics, Inc. Data
maze stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 100.0%
The MAZE analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $63.25, representing +163.87% upside from the current price of $23.97.
Competitors & Peers
maze competitorsStock Performance
Full HistoryAbout Maze Therapeutics, Inc.
Maze Therapeutics, Inc. a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in …
what is maze therapeutics, inc. · maze stock overview · maze therapeutics, inc. company profile · who is maze therapeutics, inc. ceo · maze NASDAQ · maze therapeutics, inc. headquarters · maze therapeutics, inc. business segments
About Stock Overview & Key Data
Maze Therapeutics, Inc. (MAZE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 31, 2025. As of the latest trading session, MAZE stock price is $23.97, with a market capitalization of $1.3B. The stock has returned +87.74% over the past 12 months and -41.95% year-to-date.
According to 6 Wall Street analysts, the consensus rating for Maze Therapeutics, Inc. stock is Buy, with an average 12-month price target of $63.25. In fiscal year 2025, Maze Therapeutics, Inc. reported revenue of — and net income of -$131.1M. For detailed data — including Maze Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Maze Therapeutics, Inc. (MAZE) stock price is $23.97. The stock is traded on NASDAQ under the ticker symbol MAZE. The 52-week range is $9.83 – $53.65.